Michael Khan
Amministratore Delegato presso Argonaute RNA Ltd.
Profilo
Michael Khan is currently the Chief Executive Officer at Argonaute RNA Ltd.
He is also a member of Diabetes UK and HEART UK.
Previously, he was the Executive Director & Chief Medical Officer at Silence Therapeutics Plc from 2013 to 2016.
He also worked as the Head-Molecular Medicine & Associate Professor at the University of Warwick.
Dr. Khan holds a doctorate degree from University College London.
Posizioni attive di Michael Khan
| Società | Posizione | Inizio |
|---|---|---|
| HEART UK | Corporate Officer/Principal | - |
| Diabetes UK | Corporate Officer/Principal | - |
Argonaute RNA Ltd.
 Argonaute RNA Ltd. Miscellaneous Commercial ServicesCommercial Services Argonaute RNA Ltd. develops safe and reliable methods of temporarily silencing target genes in different tissue cells. The company is based in Bristol, UK. Michael Khan has been the CEO of the British company since 2021. | Amministratore Delegato | 01/01/2021 |
Precedenti posizioni note di Michael Khan
| Società | Posizione | Fine |
|---|---|---|
| SILENCE THERAPEUTICS PLC | Direttore Tecnico/Scientifico/R&S | 17/06/2016 |
| University of Warwick | Corporate Officer/Principal | - |
Formazione di Michael Khan
| University College London | Doctorate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 1 |
|---|---|
| SILENCE THERAPEUTICS PLC | Commercial Services |
| Aziende private | 3 |
|---|---|
| Diabetes UK | |
| HEART UK | |
Argonaute RNA Ltd.
Argonaute RNA Ltd. Miscellaneous Commercial ServicesCommercial Services Argonaute RNA Ltd. develops safe and reliable methods of temporarily silencing target genes in different tissue cells. The company is based in Bristol, UK. Michael Khan has been the CEO of the British company since 2021. | Commercial Services |
- Borsa valori
- Insiders
- Michael Khan
